Preparation and application of compound with 1H-benzimidazole structure
By developing a novel ASK1 inhibitor with 1H-benzimidazole structure, the problem of insufficient efficiency and specificity of existing MAP3K5 inhibitors in the treatment of various diseases has been solved, and higher therapeutic effects and potential have been achieved.
Patent Information
- Application Number
- CN202410144092.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-10
- Filing Date
- 2024-02-01
- Publication Date
- 2025-03-07
AI Technical Summary
Existing MAP3K5 inhibitors have problems with insufficient efficiency and specificity in the treatment of a variety of diseases, such as liver, lung, kidney diseases and tumors.
A novel ASK1 inhibitor with 1H-benzimidazole structure was developed to improve the inhibitory effect of MAP3K5 through specific compound structure design and expand the therapeutic potential for a variety of diseases.
This new ASK1 inhibitor significantly improves the inhibitory ability of MAP3K5, enhances the therapeutic effect on a variety of diseases such as liver, lung, kidney diseases and tumors, and provides higher therapeutic potential and specificity.
Smart Images

Figure QLYQS_1 
Figure QLYQS_3 
Figure QLYQS_4
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to the preparation and application of a compound with a 1H-benzimidazole structure. Background Art
[0002] Mitogen-activated protein kinase 5 (MAP3K5), also known as ASK1, MAPKKK5, MEKK5, is a member of the MAP3K family and is located upstream of Jun N-terminal kinase (JNK) and p38. A large number of experiments have shown that MAP3K5 plays an important role in mammalian cell stress response and induction of apoptosis-related diseases.
[0003] The latest studies have shown that MAP3K5 kinase inhibitors have potential therapeutic prospects for the treatment of common liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, chronic liver disease, metabolic liver disease, liver fibrosis, primary sclerosing cholangitis, liver ischemia-reperfusion injury, primary biliary cirrhosis, diabetes-related liver diseases, etc. Biological and medical related studies have also shown that ASK1 kinase kinase inhibitors have therapeutic effects on lung diseases (such as pulmonary hypertension and pulmonary fibrosis). In addition, inhibiting ASK1 kinase also has the feasibility of treating kidney diseases (glomerulonephritis, diabetic nephropathy, hypertensive nephropathy) and tumors. Inhibiting ASK1 kinase activity has a significant therapeutic effect in diabetic mouse models; the use of ASK1 small molecule inhibitor GS-444217 can reduce diabetic parameters. Therefore, MAP3K5 is a potential target for the treatment of the above diseases, and the development of new MAP3K5 inhibitors is of great significance for alleviating or even curing these diseases.
[0004] Hematopoietic progenitor kinase 1 (HPK1), also known as MAP4K1, is a hematopoietic-specific protein serine-threonine kinase and a member of the mammalian Ste20-related protein kinase MAP4K family. MAP4K family kinases have highly similar protein structures and play an important role in regulating cell survival, cell migration, apoptosis and autophagy.
[0005] MAP4K1 is mainly expressed in lymphoid organs / tissues, including bone marrow, lymph nodes, thymus, spleen, placenta, and fetal liver; it is expressed in all hematopoietic cells and immune cells, such as hematopoietic progenitor cells, T cells, B cells, macrophages, dendritic cells, neutrophils, and mast cells. As an immune factor, MAP4K1 plays an important role in immune response, and can transduce MAP3K signals in the MAPK family to MAP2K, causing JNK activation. Studies have shown that downregulated MAP4K1 expression levels have been detected in peripheral blood monocytes and T cells of patients with autoimmune diseases such as systemic lupus erythematosus and psoriatic arthritis. In addition, MAP4K1 is associated with the occurrence and development of a variety of malignant tumors; MAP4K1 is positively correlated with a variety of T cell exhaustion signals (CD3E, TIGIT, PDCD1, CTLA4, HAVCR2 and LAG3); at the same time, the expression level of HPK1 is negatively correlated with the survival time of patients with a variety of tumors, such as low-grade gliomas of the brain, renal clear cell carcinoma, pancreatic cancer, and invasive breast cancer. MAP4K1 induces tumor-infiltrating T cell disorders and weakens the immune response of T cells, B cells and dendritic cells, making it a potential target for tumor immunotherapy.
[0006] MAP3K5 and MAP4K1 both play an important role in inducing apoptosis-related diseases. Therefore, targeted inhibition of MAP3K5 and MAP4K1 can synergistically treat the above-related diseases. The development of dual-target inhibitors of MAP3K5 and MAP4K1 is of great significance for the treatment of tumors, liver and other diseases. Summary of the invention
[0007] The purpose of the present invention is to provide a class of ASK1 inhibitors with novel structures.
[0008] The present invention also aims to provide a preparation method and use of a compound having a 1H-benzimidazole structure.
[0009] The first aspect of the present invention provides a compound having a 1H-benzimidazole structure as described in formula (I), or an enantiomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0010]
[0011] Wherein, R1 is selected from any one or a combination of the following: H, alkyl, aromatic acyl, aromatic alkyl, phenyl formate, formamide, substituted or unsubstituted 5-12 membered heteroaromatic ring containing N, O or S atoms, substituted or unsubstituted 5-13 membered saturated heterocyclic ring containing N, O or S atoms, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl, substituted or unsubstituted C2-C4 alkynyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkylethynyl, substituted or unsubstituted C1-C4 alkylamino, substituted or unsubstituted C1-C4 alkylcarbonylamino, substituted or unsubstituted C1-C4 alkoxycarbonylamino, substituted or unsubstituted C1-C4 sulfonyl, substituted or unsubstituted C1-C4 alkyl-S-, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C1-C4 alkylaminocarbonyl;
[0012] R2 is selected from any one or a combination of the following: halogen, hydroxyl, amino, nitro, oxy, alkyl, substituted or unsubstituted 5-12 membered heteroaromatic ring containing N, O or S atoms, substituted or unsubstituted 5-13 membered saturated heterocyclic ring containing N, O or S atoms, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl, substituted or unsubstituted C2-C4 alkynyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkylethynyl, substituted or unsubstituted C1-C4 alkylamino, substituted or unsubstituted C1-C4 alkylcarbonylamino, substituted or unsubstituted C1-C4 alkoxycarbonylamino, substituted or unsubstituted C1-C4 sulfonyl, substituted or unsubstituted C1-C4 alkyl-S-, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C1-C4 alkylaminocarbonyl;
[0013] A means S or O;
[0014] It represents a 6-membered aromatic ring containing 0-2 N atoms, including but not limited to benzene ring, pyridine, pyrazine, and the N atoms are substituted at different positions on the ring;
[0015] R3 represents a substituted or unsubstituted 5-6 membered heteroaromatic ring containing 1-4 heteroatoms of N, O or S, wherein one or more hydrogen atoms on the substituent group of the 5-6 membered heteroaromatic ring containing 1-4 heteroatoms of N, O or S are substituted by a group selected from the group consisting of halogen, deuterium atom, cyano, hydroxyl, amino, nitro, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy; wherein one or more hydrogen atoms on the substituent group of the substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy are substituted by a group selected from the group consisting of hydroxyl, amino, carboxyl.
[0016] Preferably, the compound comprises the general structural formula (I-1) and (I-2):
[0017]
[0018] The compound of the present invention is selected from one of the following structural formulas:
[0019]
[0020] The present invention also provides a method for preparing the compound having a 1H-benzimidazole structure, comprising the following steps:
[0021]
[0022] The compound of formula (I) is prepared by a one-step reaction in step 1, and step 1 is route 1 or route 2:
[0023] The first route comprises: mixing carboxylic acid S1 and corresponding amine S2 in a solvent, adding 1-propylphosphoric anhydride (T3P) or 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), adding a base, and reacting at room temperature or 40° C. to obtain a compound represented by formula (I-1);
[0024] The second route comprises: mixing carboxylic acid S1 and corresponding amine S2 in a solvent, adding alkali or phosphorus oxychloride, and reacting at room temperature or at 40° C. to obtain a compound represented by formula (I-1).
[0025] The step 2 comprises: adding the compound of formula (I-1) (0.14 mmol) and Lawesson reagent (84.5 mg, 0.21 mmol) to toluene, raising the temperature to reflux and stirring overnight to react to obtain the compound of formula (I-2).
[0026] Preferably, the preparation of the carboxylic acid S1 comprises the following steps:
[0027]
[0028] The step 1 comprises: adding 2-hydroxyacetic acid and 5.5M HCl solution to a reaction bottle containing compound M1, heating to reflux, and maintaining the reaction for 12 hours, cooling to room temperature, adding ammonia water dropwise until a precipitate is formed, filtering the precipitate, washing with water, and finally drying to obtain product M2, and the product M2 is directly used for the next reaction; the equivalent ratio of compound M1 to 2-hydroxyacetic acid is 1:1.5.
[0029] Step 2: Mix the product M2 (1.0 equivalent) with an aqueous base such as 1N sodium hydroxide aqueous solution (2.0 equivalents), react at 100°C with stirring for 2 hours, cool to room temperature, add KMnO4 (1.5 equivalents) for oxidation, and then heat to 100°C for 10 hours. After the reaction is completed, cool to room temperature, filter out the insoluble solid, adjust the filtrate to pH 4 with 2M HCl, and a precipitate will appear. Collect the precipitated solid by filtration, wash with water, and dry to obtain carboxylic acid S1; the equivalent ratio of the base, product M2, and KMnO4 is 2:1:1.5, and the aqueous base includes 1N sodium hydroxide aqueous solution.
[0030] Preferably, the solvent is any one of the following substances: tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, or N, N-dimethylformamide, toluene, pyridine, and the base is any one of the following substances: triethylamine, diisopropylethylamine.
[0031] Another aspect of the present invention is to provide a compound of the present invention or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof.
[0032] The present invention also provides an ASK1 inhibitor, which includes the compound having a 1H-benzimidazole structure, or its enantiomers, diastereomers, racemates and mixtures thereof, or its pharmaceutically acceptable salts, crystalline hydrates or solvates.
[0033] The present invention also provides a pharmaceutical composition comprising: (A) a therapeutically effective amount of the compound having a 1H-benzimidazole structure, or one or more of its enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof; and (B) a pharmaceutically acceptable carrier.
[0034] Preferably, the pharmaceutical composition optionally further comprises a pharmaceutically acceptable excipient, which is selected from the following group: an adhesive, a filler, a diluent, a disintegrant, a suspending agent, a suspending aid, a sustained (controlled) release agent, a lyoprotectant, a coating agent, an enteric material, a lubricant, a glidant, an anti-adherent, a sweetener, a flavoring agent, a plasticizer, a sunscreen, a solubilizer, a humectant, a solvent, an osmotic pressure regulator, a colorant, a pigment, a surfactant, an emulsifier, a water-soluble matrix, a fat-soluble matrix, an oily matrix, a pore-forming agent, a gelling agent, a preservative, a buffer, a chelating agent, an antioxidant, or a combination thereof.
[0035] The present invention also provides an application of the compound in preparing a drug for treating a disease related to the activity or expression level of ASK1 kinase.
[0036] Preferably, the disease associated with the activity or expression of ASK1 kinase is selected from one of liver disease, lung disease, cardiovascular disease, kidney disease, metabolic disease and tumor disease.
[0037] The liver disease is selected from one of non-alcoholic fatty liver, non-alcoholic steatohepatitis, chronic liver disease, metabolic liver disease, liver fibrosis, primary sclerosing cholangitis, liver ischemia-reperfusion injury, primary biliary cirrhosis and diabetes-related liver disease. The lung disease is selected from pulmonary hypertension and pulmonary fibrosis. The cardiovascular disease is selected from heart failure and the like. The kidney disease is selected from one of glomerulonephritis, diabetic nephropathy and hypertensive nephropathy. The metabolic disease is selected from one of type 2 diabetes and type 1 diabetes. The tumor disease is selected from one of liver cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, esophageal cancer, cervical cancer, ovarian cancer, bladder cancer and pancreatic cancer. DETAILED DESCRIPTION
[0038] definition
[0039] Unless otherwise defined below, the meanings of all technical and scientific terms used herein are intended to be the same as those generally understood by those skilled in the art. Reference to the technology used herein is intended to refer to the technology generally understood in the art, including those changes in technology or replacement of equivalent technology that are obvious to those skilled in the art. Although the detailed terms are well understood by those skilled in the art, the following definitions are still set forth to better explain the present invention.
[0040] As used herein, the terms "including," "comprising," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0041] As used herein, the term "hydrogen" refers to protium (H), deuterium (D), tritium (T).
[0042] As used herein, the term "alkyl" is defined as an offline or branched saturated aliphatic hydrocarbon. 1-12 Alkyl refers to a group having 1 to 12, for example 1 to 6, carbon atoms (C 1-6 Alkyl) or 1 to 4 carbon atoms (C 1-4 For example, as used herein, the term "C 1-6 "Alkyl" refers to an offline or branched group of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl), which is optionally substituted with 1 or more (e.g., 1 to 3) suitable substituents such as halogen (in which case the group is referred to as "haloalkyl") (e.g., CH2F, CHF2, CF3, CCl3, C2F5, C2Cl5, CH2CF3, CH2Cl or -CH2CH2CF3, etc.). The term "C 1-4 "Alkyl" refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
[0043] As used herein, the term "alkenyl" means an offline or branched monovalent hydrocarbon radical containing one or more double bonds and having 2 to 6 carbon atoms ("C 2-6 The alkenyl group is, for example, vinyl, 1-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl. When the compound of the present invention contains an alkenyl group, the compound may be present in the pure E (entgegen) form, the pure Z (zusammen) form or a mixture thereof in any ratio.
[0044] As used herein, the term "alkynyl" refers to a monovalent hydrocarbon group containing one or more triple bonds, for example having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.
[0045] As used herein, the term "cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or a bicyclic ring, including a spirocyclic, fused or bridged system (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.)), which is optionally substituted with 1 or more (such as 1 to 3) suitable substituents. The cycloalkyl has 3 to 15 carbon atoms. For example, the term "C 3-6"Cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring of 3 to 6 ring carbon atoms (for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), which is optionally substituted by 1 or more (such as 1 to 3) suitable substituents, for example methyl substituted cyclopropyl.
[0046] As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated monovalent monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms or one or more (e.g., one, two, three or four) heteroatom-containing groups selected from C(=O), O, S, S(=O), S(=O)2 and NRa in the ring, wherein Ra represents a hydrogen atom.
[0047] As used herein, the term "5-12 membered heteroaromatic ring" refers to a monocyclic aromatic group having 5-12 ring members, and at least one (e.g., 1, 2, 3 or 4) saturated heteroatoms selected from N, O, and S in the ring members, for example, "5-6 membered heteroaryl", 5 membered heteroaryl, 6 membered heteroaryl, etc. Specific examples include, but are not limited to, furanyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, pyridyl, 2-pyridonyl, 4-pyridonyl, pyrimidinyl, 2H-1,2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4-oxazinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, 1,2,4,5-tetrazinyl, and the like.
[0048] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0049] As used herein, the term "substitution" refers to the replacement of one or more (e.g., one, two, three, or four) hydrogens on the designated atom with a selection from the indicated group, provided that the normal valence of the designated atom in the present context is not exceeded and the substitution forms a stable compound. Combinations of substituents and / or variables are permitted only if such combinations form stable compounds.
[0050] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0051] The present invention also includes all pharmaceutically acceptable isotope-labeled compounds, which are identical to the compounds of the present invention, except that one or more atoms are replaced by atoms having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Isotopes suitable for inclusion in the compounds of the present invention, such as deuterium ( 2 H) Tritium 3 H)): Carbon isotopes (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (e.g. 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); isotopes of oxygen (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (e.g. 32 P); isotopes of sulfur (e.g. 35 S). Certain isotopically labeled compounds of the invention (e.g., incorporating a radioactive isotope) are useful in drug and / or substrate tissue distribution studies (e.g., assays). The radioactive isotope tritium ( 3 H) and carbon-14 ( 14 C) is particularly useful for this purpose because it is incorporated and easily detected. 11 C. 18 F. 15 O and 13 N) can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotope-labeled compounds of the present invention can be prepared by methods similar to those described in the accompanying routes and / or examples and preparations by using appropriate isotope-labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent can be isotopically substituted, for example, D2O, acetone-d6 or DMSO-d6.
[0052] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
[0053] Suitable acid addition salts are formed from acids that form pharmaceutically acceptable salts, examples include aspartate, gluconate, lactate, palmitate, hydrochloride and other similar salts.
[0054] Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts. Examples include aluminum, sodium, calcium, potassium, choline and other similar salts.
[0055] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain polar solvents as structural elements of the crystal lattice of the compounds, in particular water, methanol or ethanol. The amount of polar solvents, in particular water, may exist in a stoichiometric ratio or in a non-compound stoichiometric ratio.
[0056] The term "about" means within ±10% of the stated numerical value, preferably within ±5%, more preferably within ±2%.
[0057] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by mass.
[0058] Table 1 below shows the specific structural formulas and Chinese names of 21 small molecule compounds having 1H-benzimidazole-3-carboxamide structure.
[0059] Table 1
[0060]
[0061]
[0062]
[0063] The specific preparation methods of the above 21 small molecule compounds having 1H-benzimidazole-3-carboxamide structure are as follows:
[0064] 1. Preparation of 9 intermediates
[0065] Synthetic intermediate 01: 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (12-4-41)
[0066]
[0067] Step 1: Dissolve methyl 6-aminopicolinate (500 mg, 3.289 mmol) in 25 mL of methanol, slowly add hydrazine hydrate (318.75 μL, 6.578 mmol) under argon atmosphere, raise the temperature to 75 ° C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. 475 mg of the crude target compound (12-3-41) is obtained as a white solid with a yield of 95%.
[0068] Step 2: Dissolve 6-amino-picolinocarboxylic acid hydrazide (475 mg, 3.125 mmol) in 30 mL of toluene, add N,N-dimethylformamide dimethyl acetal (104.74 μL, 9.375 mmol) and isopropylamine (157.5 μL, 21.875 mmol). Cool to 0 ° C, add acetic acid (45.1 μL, 9.375 mmol) dropwise. Under argon environment, raise the temperature to 95 ° C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 10 mL of pure water, and continue to react at 85 ° C for 10 h. After the reaction is completed, add 20 mL of ether for washing, 20 mL of dichloromethane for washing, dry over anhydrous sodium sulfate, concentrate by rotary evaporation, and purify by column chromatography (petroleum ether / ethyl acetate = 20 / 1). The target compound is 243.485 mg of pure white solid (12-4-41) with a yield of 51.3%. 1 H NMR (400MHz, DMSO-d6): δ8.78(s,1H),7.52(dd,J=8.1,7.6Hz,1H),7.23-7.13(m ,1H),6.58-6.47(m,1H),δ5.53(dt,J=13.5,6.7Hz,1H).,1.43(d,J=6.7Hz,6H).
[0069] Synthetic intermediate 02: 3-(4-isopropyl-4H-1,2,4-triazol-3-yl)aniline (33-83-40)
[0070]
[0071] Step 1: Dissolve methyl 3-aminobenzoate (500.0 mg, 3.3 mmol) in 10 mL of methanol, slowly add hydrazine hydrate (320.0 μL, 6.6 mmol) under argon atmosphere, raise the temperature to 75°C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. A crude white solid target compound (498.0 mg, 33-68-32) is obtained with a yield of 100.0%.
[0072] Step 2: Dissolve 3-aminobenzoyl hydrazide (498 mg, 9.8 mmol) in 10 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.3 mL, 9.8 mmol) and isopropylamine (1.4 mL, 16.4 mmol). Cool to 0 ° C, add acetic acid (1.05 mL, 9.8 mmol) dropwise. Under argon environment, raise the temperature to 95 ° C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 15 mL of pure water, and continue to react at 85 ° C for 10 h. After the reaction is completed, add 20 mL of ether for washing, take the water layer, wash with 20 mL of dichloromethane, take the organic layer, and dry it with anhydrous sodium sulfate, concentrate it by rotary evaporation, and purify it by column chromatography (dichloromethane / methanol = 50 / 1). The target compound is a pure white solid 327 mg (33-83-40), with a yield of 50.6%. 1 H NMR (400MHz, CDCl3): δ8.33(s,1H),7.26(t,J=8.0Hz,1H),6.92(s,1H),6.86(d,J= 7.6Hz, 1H), 6.81 (dd, J = 8.0, 1.6Hz, 1H), 4.60-4.48 (m, 1H), 1.47 (d, J = 6.4Hz, 6H).
[0073] Synthetic intermediate 03: 4-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (33-76-38)
[0074]
[0075] Step 1: Dissolve 2-aminoisonicotinate (500.0 mg, 3.3 mmol) in 10 mL of methanol, slowly add hydrazine hydrate (320.0 μL, 6.6 mmol) under argon atmosphere, raise the temperature to 75°C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. 500 mg of crude white solid target compound (33-69-33) is obtained with a yield of 100.0%.
[0076] Step 2: Dissolve 2-aminoisonicotinic acid hydrazide (500.0 mg, 3.3 mmol) in 10 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.3 mL, 9.8 mmol) and isopropylamine (1.4 mL, 16.45 mmol). Cool to 0 ° C, add acetic acid (0.6 mL, 9.8 mmol) dropwise. Under argon environment, raise the temperature to 95 ° C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 15 mL of pure water, and continue to react at 85 ° C for 10 h. After the reaction is completed, add 20 mL of ether for washing, take the water layer, wash with 20 mL of dichloromethane, take the organic layer, and dry it with anhydrous sodium sulfate, concentrate it by rotary evaporation, and purify it by column chromatography (dichloromethane / methanol = 50 / 1). The target compound is a pure yellow solid 540.0 mg (33-76-38), with a yield of 31.3%. 1 H NMR (400MHz, CDCl3): δ8.32(s,1H),8.13(d,J=5.2Hz,1H),6.79(s,1H),6.69( dd,J=5.2,1.2Hz,1H),5.09(s,2H),4.56-4.42(m,1H),1.45(d,J=6.8Hz,6H).
[0077] Synthetic intermediate 04: 5-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-3-amine (33-100-37)
[0078]
[0079] Step 1: Dissolve 5-aminonicotinic acid methyl ester (500.0 mg, 3.3 mmol) in 10 mL of methanol, slowly add hydrazine hydrate (320.0 μL, 6.6 mmol) under argon atmosphere, raise the temperature to 75°C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. 500.0 mg (33-91-35) of crude white solid target compound is obtained with a yield of 100.0%.
[0080] Step 2: Dissolve 5-aminonicotinic acid hydrazide (500.0 mg, 3.3 mmol) in 10 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.3 mL, 9.8 mmol) and isopropylamine (1.4 mL, 16.45 mmol). Cool to 0 ° C, add acetic acid (0.6 mL, 9.8 mmol) dropwise. Under argon environment, raise the temperature to 95 ° C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 15 mL of pure water, and continue to react at 85 ° C for 10 h. After the reaction is completed, add 20 mL of ether for washing, take the water layer, wash with 20 mL of dichloromethane, take the organic layer, and dry it with anhydrous sodium sulfate, concentrate it by rotary evaporation, and purify it by column chromatography (dichloromethane / methanol = 50 / 1). The pure product of the target compound is a yellow oily liquid 652.5 mg (33-100-37), and the yield is 98.0%. 1 HNMR (400MHz, DMSO-d6): δ8.87 (s, 1H), 8.07 (d, J = 2.8Hz, 1H), 7.91-7.87 (m, 1H), 7.10 (t, J = 2.0Hz, 1H), 4.45-4.32 (m, 1H), 1.41 (d, J = 6.8Hz, 6H).
[0081] Synthetic intermediate 05: 2-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-4-amine (28-105-41)
[0082]
[0083] Step 1: Dissolve methyl 4-aminopicolinate (500 mg, 3.289 mmol) in 10 mL of methanol, slowly add hydrazine hydrate (318.75 μL, 6.578 mmol) under argon atmosphere, raise the temperature to 75 ° C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. A crude white solid target compound of 475 mg (28-103-30) is obtained with a yield of 95.0%.
[0084] Step 2: Dissolve 4-amino-picolinocarboxylic acid hydrazide (475 mg, 3.125 mmol) in 15 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.24 mL, 9.375 mmol) and isopropylamine (1.33 mL, 15.625 mmol). Cool to 0 ° C, add acetic acid (534.85 μL, 9.375 mmol) dropwise. Under argon environment, raise the temperature to 95 ° C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 10 mL of pure water, and continue to react at 85 ° C for 10 h. After the reaction is completed, add 20 mL of ether for washing, take the water layer, wash with 20 mL of dichloromethane, take the organic layer, and dry it with anhydrous sodium sulfate, concentrate it by rotary evaporation, and purify it by column chromatography (dichloromethane / methanol = 50 / 1). The target compound is pure white solid 203.0 mg (28-105-41), with a yield of 30.4%. 1 H NMR (400MHz, CDCl3): δ8.28 (s, 1H), 8.15 (d, J = 5.6Hz, 1H), 7.50 (d, J = 2.4Hz, 1H), 6.53 (dd, J = 5.6, 2.4Hz, 1H), 4.75-4.63 (m, 1H), 1.44 (d, J = 6.8Hz, 6H).
[0085] Synthetic intermediate 06: 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyrazin-2-amine (33-97-38)
[0086]
[0087] Step 1: Dissolve methyl 6-aminopyrazine-2-carboxylate (500 mg, 3.268 mmol) in 10 mL of methanol, slowly add hydrazine hydrate (318.75 μL, 6.536 mmol) under argon atmosphere, raise the temperature to 75°C and reflux for 3 h. After the reaction is complete, cool to room temperature, dry over anhydrous sodium sulfate, and concentrate by rotary evaporation. Obtain 450.0 mg (33-92-34) of crude white solid target compound with a yield of 90.0%.
[0088] Step 2: Dissolve 6-aminopyrazine-2-carbohydrazide (450 mg, 2.941 mmol) in 15 mL of toluene, add N,N-dimethylformamide dimethyl acetal (867.09 μL, 8.823 mmol) and isopropylamine (1.25 mL, 14.75 mmol). Cool to 0°C, and drop acetic acid (504.17 μL, 8.823 mmol). Under argon atmosphere, raise the temperature to 95°C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 10 mL of pure water, and continue to react at 85°C for 10 h. After the reaction, 20 mL of ether was added for washing. The aqueous layer was taken and washed with 20 mL of dichloromethane. The organic layer was taken and dried over anhydrous sodium sulfate, concentrated by rotary evaporation, and purified by column chromatography (dichloromethane / methanol = 50 / 1) to obtain 260.0 mg of the target compound as a pure yellow solid (33-97-38) with a yield of 39.1%. 1 HNMR (400MHz, CDCl3): δ8.78 (s, 1H), 8.38 (s, 1H), 8.05 (s, 1H), 5.52-5.39 (m, 1H), 1.53 (d, J = 6.8Hz, 6H).
[0089] Synthetic intermediate 07: 6-(1-isopropyl-1H-pyrazol-5-yl)pyridin-2-amine (33-110-36)
[0090]
[0091] Step 1: A mixture of 6-bromopyridin-2-amine (53.7 mg, 0.31 mmol), 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (90.0 mg, 1.2 mmol), Xphos-Pd-G2 (24.3 mg, 0.1 mmol) and Na2CO3 (33.8 mg, 0.31 mmol) in dioxane / H2O (5 mL / 1 mL) was heated at 100°C under an argon atmosphere for 4 hours. After completion, the resulting mixture was dissolved in water and extracted with CH2Cl2 (30 mL×3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was separated by silica gel chromatography to obtain the target compound as a white solid 55.9 mg (33-110-36) with a yield of 89.7%. 1H NMR (400MHz, CDCl3): δ7.53(d,J=1.6Hz,1H),7.50(dd,J=8.4,7.6Hz,1H),6.87(dd,J=7.2,0.8Hz,1H),6 .48(dd,J=8.4,0.8Hz,1H),6.43(d,J=2.0Hz,1H),5.38-5.26(m,1H),4.59(s,2H),1.50(d,J=6.4Hz,6H).
[0092] Synthetic intermediate 08: 6-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (33-88-39)
[0093]
[0094] Step 1: Dissolve 6-amino-picolinohydrazide (28-55-35, 475.0 mg, 3.13 mmol) in 15 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.24 mL, 9.38 mmol) and cyclopropylamine (1.24 mL, 21.88 mmol). Cool to 0°C, add acetic acid (534.85 μL, 9.38 mmol) dropwise. Under argon atmosphere, raise the temperature to 95°C and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 10 mL of pure water, and continue to react at 85°C for 10 h. After the reaction, add 20 mL of ether for washing, take the aqueous layer, wash with 20 mL of dichloromethane, take the organic layer, and dry it over anhydrous sodium sulfate, concentrate it by rotary evaporation, and purify it by column chromatography (dichloromethane / methanol=50 / 1). The target compound is a pure white solid 314.1 mg (33-88-39), 50.7%. 1 H NMR (400MHz, CDCl3): δ8.14(s,1H),7.53(t,J=8.0Hz,1H),7.46(d,J=7.2Hz,1H),6.58 (d,J=8.0Hz,1H),3.91-3.81(m,1H),1.05(dd,J=13.4,6.4Hz,2H),0.89-0.82(m,2H).
[0095] Synthetic intermediate 09: 6-(4-cyclopentyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine (33-93-36)
[0096]
[0097] Step 1: Dissolve 6-amino-picolinohydrazide (28-55-35, 475.0 mg, 3.13 mmol) in 15 mL of toluene, add N,N-dimethylformamide dimethyl acetal (1.24 mL, 9.38 mmol) and cyclopentylamine (1.24 mL, 21.88 mmol). Cool to 0°C, add acetic acid (534.85 μL, 9.38 mmol) dropwise. Raise the temperature to 95°C under argon atmosphere and reflux for 10 h, then cool to room temperature, concentrate on a rotary evaporator, dissolve in 10 mL of pure water, and continue to react at 85°C for 10 h. After the reaction, 20 mL of ether was added for washing, the aqueous layer was taken, and then washed with 20 mL of dichloromethane. The organic layer was taken and dried over anhydrous sodium sulfate, concentrated by rotary evaporation, and purified by column chromatography (dichloromethane / methanol=50 / 1 to obtain 125.9 mg (33-93-36) of pure white solid target compound, 17.6%. 1 HNMR (400MHz, CDCl3): δ8.28 (s, 1H), 7.59-7.50 (m, 2H), 6.58 (dd, J = 8.0, 1.2Hz, 1H), 5.63-5.50 (m, 1H), 2.30-2.18 (m, 2H), 1.92-1.69 (m, 6H).
[0098] 2. Synthesis of 21 compounds with 1H-benzimidazole structures
[0099] Example 1: Final product 01
[0100] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (01,12-166-41)
[0101]
[0102] 1H-Benzo[d]imidazole-2-carboxylic acid (50 mg, 0.308 mmol) and intermediate 01 (12-4-41, 52.2 mg, 0.26 mmol) were dissolved in 5 mL of dichloromethane, cooled to 0°C, and triethylamine (250 μL, 1.80 mmol) and 1-propylphosphoric anhydride (612.0 μL, 2.06 mmol) were added. Under argon atmosphere, the temperature was raised to 40°C and refluxed for 7 h. After the reaction was completed, 20 mL of saturated sodium bicarbonate aqueous solution was added for washing, dried over anhydrous sodium sulfate, concentrated by rotary evaporator, and purified by reverse phase silica gel column (dichloromethane / methanol=80 / 1) to obtain a pure white solid product, i.e., the target compound 01 (12-166-41) 12.3 mg, with a yield of 11.4%. 1HNMR (400MHz, CD3OD): δ8.85(s,1H),8.45(d,J=8.3Hz,1H),8.06(t,J=8.0Hz,1H),7.94(d,J=7.7Hz,1H),7.80(s ,1H),7.63(s,1H),7.40(s,2H),7.27(dd,J=6.1,3.0Hz,1H),5.80(m,J=13.4,6.7Hz,1H),1.62(d,J=6.7Hz,6H).
[0103] Example 2: Final product 02
[0104] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazole-2-carboxamide (02,12-177-42)
[0105]
[0106] 1-Methyl-1H-benzo[d]imidazole-2-carboxylic acid (103.0 mg, 0.59 mmol) and intermediate 01 (12-4-41, 99.0 mg, 0.49 mmol) were dissolved in 5 mL of dichloromethane, cooled to 0°C, and triethylamine (474 μL, 3.42 mmol) and 1-propylphosphoric anhydride (1.2 mL, 3.91 mmol) were added. Under argon atmosphere, the temperature was raised to 40°C and refluxed for 7 h. After the reaction was completed, 20 mL of saturated sodium bicarbonate aqueous solution was added for washing, dried over anhydrous sodium sulfate, concentrated by rotary evaporator, and purified by reverse phase silica gel column (dichloromethane / methanol=80 / 1) to obtain 51.7 mg of pure yellow-white solid, i.e., target compound 02 (12-177-42), with a yield of 24.4%. 1 H NMR (400MHz, CD3OD): δ8.83(s,1H),8.43(d,J=8.3Hz,1H),8.05(t,J=8.0Hz,1H),7.92(d,J=7.6Hz,1H),7.80(d,J=8 .1Hz,1H),7.65(d,J=8.2Hz,1H),7.51-7.32(m,3H),5.74(m,J=13.5,6.7Hz,1H),4.28(s,3H),1.61(d,J=6.7Hz,6H).
[0107] Example 3: Final product 03
[0108] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-methylsulfamide (03, 20-23-41)
[0109]
[0110] Add N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (12-166-41, 50.0 mg, 0.14 mmol) and Lawesson's reagent (84.5 mg, 0.21 mmol) to 4 mL of toluene. Raise the temperature to reflux and stir overnight. After the reaction is completed, concentrate, add sodium bicarbonate water and dichloromethane to extract, combine the dichloromethane phases, concentrate on a rotary evaporator, and obtain 13.0 mg of a white solid by column chromatography, that is, the target compound 03 (20-23-41), 24.8%. 1 HNMR (400MHz, CDCl3): δ8.43(s,1H),8.35(d,J=8.3Hz,1H),8.04(d,J=7.1Hz,1H),7.87(t,J=8.0Hz,1H) ,7.84-7.79(m,1H),7.60(d,J=7.7Hz,1H),7.44-7.34(m,2H),5.69-5.57(m,1H),1.56(d,J=6.7Hz,6H).
[0111] Example 4: Final product 04
[0112] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-7-methyl-1H-benzo[d]imidazole-2-carboxamide (04, 20-13-41)
[0113]
[0114] 7-Methyl-1H-benzo[d]imidazole-2-carboxylic acid (50.0 mg, 0.28 mmol) and intermediate 01 (12-4-41, 48.1 mg, 0.24 mmol) were added to 5 mL of dichloromethane. The temperature was lowered to 0°C, triethylamine (167.6 mg, 1.66 mmol) and 1-propylphosphoric acid cyclic anhydride (602.4 mg, 1.89 mmol) were added, and the temperature was raised to 40°C and stirred overnight. After the reaction was completed, the reaction solution was concentrated, water was added and extracted with dichloromethane, the organic phases were combined, and the organic phases were dried with anhydrous Na2SO4, concentrated by rotary evaporator, and 28 mg of slightly yellow solid was obtained by column chromatography to obtain the target compound 04 (20-13-41), 32.8%. 1H NMR (400MHz, CDCl3): δ8.45 (d, J = 8.2Hz, 1H), 8.36 (s, 1H), 8.12-8.04 (m, 2H), 7.93-7 .83(m,2H),7.51-7.46(m,1H),5.81-5.68(m,1H),1.60(d,J=6.8Hz,6H),1.18(s,3H).
[0115] Example 5-13 Synthesis of final product 05-13
[0116] Synthesis of Intermediates S1a-S1i Indazole Carboxylic Acids
[0117] General method for the synthesis of intermediates S1a, S1b, S1c, S1d, S1e, S1f, S1g, S1h, S1i indazole carboxylic acids:
[0118]
[0119] Step 1: Add 2-hydroxyacetic acid (228.1 mg, 3.0 mmol) and 5.5 M HCl (5 mL) to a reaction bottle containing M1 compound (compounds M1a-M1i, respectively) (2 mmol), stir, and then heat to reflux under argon protection for 12 hours. After the reaction is completed, cool to room temperature and add ammonia water dropwise until a precipitate is formed. Filter the precipitate, wash with water, and finally dry to obtain the target compounds M2a-M2i, which are directly used in the next step reaction.
[0120] Intermediate M2a: (6-methyl-1H-benzo[d]imidazol-2-yl)methanol
[0121] White solid, yield: 36.6%. 1 H NMR (400MHz, DMSO-d6): δ7.56(d,J=8.4Hz,1H),7.43(s,1H),7.22(dd,J=8.4,1.2Hz,1H),2.45(s,3H).
[0122] Intermediate M2b: (7-methoxy-1H-benzo[d]imidazol-2-yl)methanol
[0123] Brown solid, yield: 45.2%. 1 H NMR (400MHz, DMSO-d6): δ7.02-6.96 (m, 2H), 6.60 (dd, J = 6.8, 2.0Hz, 1H), 4.56 (s, 2H), 3.83 (s, 3H).
[0124] Intermediate M2c: (6-methoxy-1H-benzo[d]imidazol-2-yl)methanol
[0125] Brown solid, yield: 79.8%. 1 H NMR (400MHz, DMSO-d6): δ7.37 (d, J = 8.7 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 8.7, 2.5 Hz, 1H), 4.64 (s, 2H), 3.76 (s, 3H).
[0126] Intermediate M2d: (7-fluoro-1H-benzo[d]imidazol-2-yl)methanol
[0127] Brown solid, yield: 70.1%. 1 H NMR (400MHz, DMSO-d6): δ7.24 (d, J=7.3Hz, 1H), 7.07 (m, J=8.0, 4.9Hz, 1H), 6.89 (dd, J=10.7, 8.3Hz, 1H), 4.64 (s, 2H).
[0128] Intermediate M2e: (6-fluoro-1H-benzo[d]imidazol-2-yl)methanol
[0129] Brown solid, yield: 75.4%. 1 H NMR (400MHz, DMSO-d6): δ7.47 (dd, J=8.7, 4.9Hz, 1H), 7.27 (dd, J=9.6, 2.5Hz, 1H), 7.03-6.95 (m, 1H), 4.68 (s, 2H).
[0130] Intermediate M2f: (7-chloro-1H-benzo[d]imidazol-2-yl)methanol
[0131] Brown solid, yield: 81.3%. 1 H NMR (400MHz, DMSO-d6): δ7.46-7.33 (m, 1H), 7.15 (d, J = 7.1Hz, 1H), 7.10-7.05 (m, 1H), 4.65 (d, J = 4.9Hz, 2H).
[0132] Intermediate M2g: (6-chloro-1H-benzo[d]imidazol-2-yl)methanol
[0133] Brown solid, yield: 90.7%. 1 H NMR (400MHz, CD3OD): δ7.53 (d, J = 1.9 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 7.20 (dd, J = 8.6, 2.0 Hz, 1H), 4.82 (s, 2H).
[0134] Intermediate M2h: (7-bromo-1H-benzo[d]imidazol-2-yl)methanol
[0135] Yellow-brown solid, yield: 84.5%. 1 H NMR (400MHz, DMSO-d6): δ7.47 (d, J = 7.8 Hz, 1H), 7.35 (dd, J = 7.7, 0.8 Hz, 1H), 7.09 (t, J = 7.9 Hz, 1H), 4.71 (d, J = 5.4 Hz, 2H).
[0136] Intermediate M2i: (6-bromo-1H-benzo[d]imidazol-2-yl)methanol
[0137] Brown solid, yield: 92.1%. 1 H NMR (400MHz, DMSO-d6): δ7.67 (s, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.28 (dd, J = 8.5, 1.9 Hz, 1H), 4.68 (s, 2H).
[0138] Step 2: Add the above reaction products M2a-M2i (1.0 eq.) and NaOH (2.0 eq.) to pure water, stir at 100°C for 2 h under argon atmosphere. Cool to room temperature, add KMnO4 (1.5 eq.) for oxidation, and heat to 100°C for reaction for 10 h. After the reaction is completed, cool to room temperature and filter the insoluble solid. Adjust the filtrate to pH 4 with 2M HCl, and the precipitated solid is collected by filtration, washed with water several times, and dried to obtain the crude target compound S1a-S1i.
[0139] Step 3: The synthesis of benzimidazole amides involves three different synthetic routes.
[0140] Route 1: Add the acid (S1a, S1b, S1c, 0.37mmol) and intermediate 01 (12-4-41, 62.48mg, 0.31mmol) to 5mL of dichloromethane. Cool to 0°C, slowly add triethylamine (218.0mg, 2.15mmol) and 1-propylphosphoric acid cyclic anhydride (783.4mg, 2.46mmol), and under argon protection, heat to 40°C and stir overnight. After the reaction is completed, concentrate the reaction solution, extract with water and dichloromethane, combine the organic phases, dry the organic phases with anhydrous Na2SO4, concentrate on a rotary evaporator, and obtain the target compounds 5, 6 and 7 by column chromatography.
[0141] Route 2: Acid (S1d-S1h, 0.28mmol) and intermediate 01 (12-14-41, 56.4mg, 0.28mmol) were added to a 50mL round-bottom flask, pyridine solution (3.0mL). The reaction was carried out in an argon environment, and then POCl3 (112.4μL, 1.11mmol) was slowly added, and the mixture was stirred at room temperature for 2h. After completion, water was added to quench, extracted with ethyl acetate three times, and the organic layer was washed with saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate, concentrated by rotary evaporator, and column chromatography to obtain the target compound 8-12.
[0142] Route 3: Acid (S1i, 50.0 mg, 0.21 mmol) was added to 5 mL DCM. Under argon protection, the temperature was lowered to 0°C, and N,N-diisopropylethylamine (DIPEA) (31.34 mg, 0.24 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (63.17 mg, 0.17 mmol) were added, and the mixture was heated to room temperature and stirred for 0.5 h. Then, intermediate 01 (12-4-41, 14.54 mg, 0.07 mmol) was added and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated, extracted with water and dichloromethane, the organic phases were combined, and the organic phases were dried over anhydrous Na2SO4, concentrated by rotary evaporator, and column chromatography was performed to obtain a slightly yellow solid, i.e., the target compound 13.
[0143] Example 5 Final product 05
[0144] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-methyl-1H-benzo[d]imidazole-2-carboxamide (05, 20-32-41)
[0145] According to the above step 3 route 1, a yellowish solid was obtained with a yield of 11.3%. 1 H NMR (400MHz, DMSO-d6): δ8.91(s,1H),8.22(d,J=8.2Hz,1H),8.08(t,J=8.0Hz,1H),7.94(dd,J=7.6,0.7Hz, 1H), 7.62 (s, 1H), 7.48 (s, 1H), 7.19 (d, J = 8.3Hz, 1H), 5.82-5.72 (m, 1H), 2.46 (s, 3H), 1.49 (d, J = 6.7Hz, 6H).
[0146] Example 6 Final product 06
[0147] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-7-methoxy-1H-benzo[d]imidazole-2-carboxamide (06, 20-130-40)
[0148] According to the above step 3 route 1, a white solid was obtained with a yield of 14.3%. 1 H NMR (400MHz, DMSO-d6): δ10.63(s,1H),8.87(s,1H),8.19(d,J=8.1Hz,1H),8.05(t,J=7.9Hz,1H),7.90(d,J=7.6Hz,1 H),7.26(t,J=7.9Hz,1H),7.18(s,1H),6.80(d,J=7.6Hz,1H),5.77-5.64(m,1H),3.94(s,3H),1.47(d,J=6.6Hz,6H).
[0149] Example 7 Final product 07
[0150] N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-methoxy-1H-benzo[d]imidazole-2-carboxamide (07, 20-34-41)
[0151] According to the above step 3 route 1, a yellow solid was obtained with a yield of 14.1%. 1 H NMR (400MHz, CDCl3): δ8.37(t,J=4.0Hz,2H),8.06(d,J=7.6Hz,1H),7.85(t,J=8.0Hz,1H ),7.63(s,1H),7.12-6.92(m,2H),5.69-5.55(m,1H),3.81(s,3H),1.54(d,J=6.7Hz,6H).
[0152] Example 8 Final product 08
[0153] 7-Fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (08, 20-110-41)
[0154] According to the above step 3 route 2, a yellow solid was obtained with a yield of 17.8%. 1H NMR (400MHz, DMSO-d6): δ13.84(s,1H),10.88(s,1H),8.81(s,1H),8.07(dd,J=7.7,4.7Hz,1H),7.97(t,J=8.0Hz,1H),7.83(dd, J=7.6,0.7Hz,1H),7.30(m,J=20.5,10.1,5.0Hz,2H),7.13-6.99(m,1H),5.68(m,J=13.3,6.6,2.8Hz,1H),1.37(d,J=6.7Hz,6H).
[0155] Example 9 Final product 09
[0156] 6-Fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (09, 20-62-41)
[0157] According to the above step 3 route 2, a yellowish solid was obtained with a yield of 16.8%. 1 H NMR (400MHz, DMSO-d6): δ8.92(s,1H),8.21(d,J=8.2Hz,1H),8.08(t,J=8.0Hz,1H),7.95(d,J=7.6Hz,1H),7 .87(dd,J=8.9,4.9Hz,1H),7.68-7.58(m,1H),7.33-7.18(m,1H),5.87-5.77(m,1H),1.49(d,J=6.7Hz,6H).
[0158] Example 10 Final product 10
[0159] 7-Chloro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (10,20-109-41)
[0160] According to the above step 3 route 2, a pale yellow solid was obtained with a yield of 18.0%. 1 H NMR (400MHz, DMSO-d6): δ8.89(d,J=7.1Hz,1H),8.18(d,J=8.1Hz,1H),8.10-8.05(m,1H),7.91(dd,J=7.6,0.8Hz,1 H), 7.55 (d, J = 7.1Hz, 1H), 7.45-7.39 (m, 1H), 7.35 (t, J = 7.8Hz, 1H), 5.70 (d, J = 28.2Hz, 1H), 1.46 (t, J = 6.9Hz, 6H).
[0161] Example 11 Final product 11
[0162] 6-Chloro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (11,20-55-41)
[0163] According to the above step 3 route 2, a yellowish solid was obtained with a yield of 18.9%. 1 H NMR (400MHz, DMSO-d6): δ8.95(s,1H),8.20(d,J=8.2Hz,1H),8.09(t,J=8.0Hz,1H),7.95(d,J=7.6 Hz,1H),7.90-7.60(m,2H),7.40(dd,J=8.6,1.4Hz,1H),5.87-5.77(m,1H),1.49(d,J=6.7Hz,6H).
[0164] Example 12 Final product 12
[0165] 7-Bromo-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (12,20-63-41)
[0166] According to the above step 3 route 2, a yellowish solid was obtained with a yield of 31.6%. 1 H NMR (400MHz, DMSO-d6): δ8.93(s,1H),8.21(d,J=8.1Hz,1H),8.10(t,J=7.9Hz,1H),7.94(d,J=7. 5Hz, 1H), 7.60 (t, J = 8.0Hz, 2H), 7.32 (t, J = 7.9Hz, 1H), 5.71-5.60 (m, 1H), 1.50 (d, J = 6.7Hz, 6H).
[0167] Example 13 Final product 13
[0168] 6-Bromo-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (13, 20-21-41)
[0169] According to the above step 3, route 3, a slightly yellow solid was obtained, 49.3%. 1H NMR (400MHz, CD3OD): δ8.91(s,1H),8.44(d,J=8.3Hz,1H),8.06(t,J=8.0Hz,1H),7.97-7.89(m ,1H),7.70-7.57(m,2H),7.50(dd,J=8.7,1.7Hz,1H),5.84-5.74(m,1H),1.61(d,J=6.7Hz,6H).
[0170] Example 14-18 Synthesis of Final Product 14-18
[0171] The general synthesis method is:
[0172]
[0173] Step 1: 1H-benzo[d]imidazole-2-carboxylic acid (23.96 mg, 0.15 mmol) and intermediate (02-06, 0.15 mmol) were added to a 50 mL round-bottom flask, and pyridine solution (3.0 mL). The reaction was carried out in an argon environment, and then POCl3 (90.64 mg, 0.59 mmol) was slowly added, and the mixture was stirred at room temperature for 2 h. After completion, water was added to quench, and ethyl acetate was extracted three times. The organic layer was washed with a saturated sodium chloride solution, and the organic phase was dried over anhydrous sodium sulfate, concentrated by a rotary evaporator, and purified by a normal phase silica gel column. The target compound 14-18 was obtained as a white solid.
[0174] Example 14 Final product 14
[0175] N-(3-(4-isopropyl-4H-1,2,4-triazol-3-yl)phenyl)-1H-benzo[d]imidazole-2-carboxamide (14,20-175-36)
[0176] According to the above step 1, a yellowish solid was obtained with a yield of 27.1%. 1 H NMR (400MHz, CD3OD): δ8.93(s,1H),8.23(s,1H),8.02-7.95(m,1H),7.72-7.67(m,2H),7.63(t,J =7.9Hz, 1H), 7.44 (d, J = 7.7Hz, 1H), 7.39-7.34 (m, 2H), 4.71-4.61 (m, 1H), 1.56 (d, J = 6.7Hz, 1H).
[0177] Example 15 Final product 15
[0178] N-(4-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (15,20-176-31)
[0179] According to the above step 1, a yellowish solid was obtained with a yield of 19.5%. 1 H NMR (400MHz, DMSO-d6): δ10.46(s,1H),10.46(s,1H),9.03(s,1H),8.62(dd,J=5.1,0.5Hz,1H),8.47(d,J=0.5Hz,1 H), 7.71 (s, 2H), 7.52 (dd, J = 5.1, 1.5Hz, 1H), 7.37 (dd, J = 6.2, 3.2Hz, 2H), 4.67-4.55 (m, 1H), 1.50 (d, J = 6.7Hz, 6H).
[0180] Example 16 Final product 16
[0181] N-(5-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1H-benzo[d]imidazole-2-carboxamide (16,20-170-32)
[0182] According to the above step 1, a yellowish solid was obtained with a yield of 35.1%. 1 H NMR (400MHz, DMSO-d6): δ9.40-9.37(m,1H),9.08(s,1H),8.67(dd,J=3.4,1.5Hz,2 H),7.89-7.69(m,2H),7.48-7.37(m,2H),4.65-4.53(m,1H),1.54(d,J=6.7Hz,6H).
[0183] Example 17 Final product 17
[0184] N-(2-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-4-yl)-1H-benzo[d]imidazole-2-carboxamide (17,20-187-33)
[0185] According to the above step 1, a yellowish solid was obtained with a yield of 38.9%. 1 H NMR (400MHz, DMSO-d6): δ11.58(s,1H),8.93(s,1H),8.82(d,J=1.1Hz,1H),8.65(d,J=5.5Hz,1H),8.02(dd,J= 5.5,1.8Hz,1H),7.90-7.57(m,1H),7.37(dd,J=6.0,2.9Hz,1H),5.51(m,J=6.6Hz,1H),1.47(d,J=6.7Hz,1H).
[0186] Example 18 Final product 18
[0187] N-6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyrazin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (18,20-171-33)
[0188] According to the above step 1, a yellowish solid was obtained with a yield of 35.1%. 1 H NMR (400MHz, DMSO-d6): δ13.71(s,1H),11.60(s,1H),9.41(s,1H),9.12(s,1H),9.01(s,1H),7. 94-7.78(m,1H),7.74-7.54(m,1H),7.49-7.27(m,2H),5.84-5.73(m,1H),1.49(d,J=6.6Hz,6H).
[0189] Example 19-21 Synthesis of Final Product 19-21
[0190] The general synthesis method is:
[0191]
[0192] Step 1: There are two routes for the synthesis of benzimidazole 2-carboxamides: route 1 and route 2.
[0193] Route 1: 1H-benzo[d]imidazole-2-carboxylic acid (24.1 mg, 0.15 mmol) and intermediate (7, 30.4 mg, 0.15 mmol) were added to a 50 mL round-bottom flask, and pyridine solution (2.0 mL). The reaction was carried out in an argon environment, and then POCl3 (91.0 mg, 0.59 mmol) was slowly added, and the mixture was stirred at room temperature for 2 h. After completion, water was added to quench, and ethyl acetate was extracted three times. The organic layer was washed with saturated sodium chloride solution, and the organic phase was dried over anhydrous sodium sulfate, concentrated by rotary evaporator, and purified by silica gel column. The target compound 19 was obtained as a white solid.
[0194] Route 2: 1H-benzo[d]imidazole-2-carboxylic acid (22.1 mg, 0.14 mmol) and intermediates (8 and 9, 0.11 mmol) were dissolved in 5 mL of dichloromethane, cooled to 0°C, and triethylamine (80.4 mg, 0.79 mmol) and 1-propylphosphoric anhydride (288.8 mg, 0.91 mmol) were added. Under argon atmosphere, the temperature was raised to 40°C and refluxed for 7 h. After the reaction was completed, 20 mL of saturated sodium bicarbonate aqueous solution was added for washing, and extracted with DCM. The organic phase was dried over anhydrous sodium sulfate, concentrated by rotary evaporator, and purified by silica gel column (dichloromethane / methanol=80 / 1) to obtain target compounds 20 and 21.
[0195] Example 19 Final product 19
[0196] N-(6-(1-isopropyl-1H-pyrazol-5-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (19, 20-155-41)
[0197] According to the above steps, route and synthesis, a pale yellow solid was obtained with a yield of 20.8%. 1 H NMR (400MHz, DMSO-d6): δ8.23(m,J=8.2,1.9,0.7Hz,1H),8.14-8.08(m,1H),7.88-7.77(m,2H),7.67(dd,J=7.6,0. 7Hz,1H),7.64(d,J=1.9Hz,1H),7.50-7.43(m,2H),6.85(d,J=1.9Hz,1H),5.90-5.78(m,1H),1.54(d,J=6.5Hz,6H).
[0198] Example 20 Final product 20
[0199] N-(6-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (20,29-3-32)
[0200] According to the above steps 1, route 2, a yellowish solid was obtained with a yield of 21.8%. 1 H NMR (400MHz, DMSO-d6): δ13.64(s,1H),10.80(s,1H),8.69(s,1H),8.29(dd,J=8.3,0.8Hz,1H),8.09(d,J=8.0Hz,1H),7.90(dd,J=7.6,0.8Hz,1 H),7.82(d,J=6.2Hz,1H),7.60(d,J=5.3Hz,1H),7.47-7.28(m,2H),4.4 6-4.34(m,1H),1.27-1.23(m,1H),1.10-1.01(m,2H),1.00-0.93(m,2H).
[0201] Example 21 Final product 21
[0202] N-(5-(4-cyclopentyl-4H-1,2,4-triazol-3-yl)pyridin-3-yl)-1H-benzo[d]imidazole-2-carboxamide (21,20-181-37)
[0203] According to the above steps 1, route 2, a white solid was obtained with a yield of 28.4%. 1H NMR (400MHz, DMSO-d6): δ10.87(s,1H),8.88(s,1H),8.19(dd,J=8.2,0.6Hz,1H),8.08(t,J=8.0Hz,1H),7.91(dd, J=7.6,0.7Hz,1H),7.81-7.65(m,2H),7.42-7.29(m,2H),5.88-5.75(m,1H),2.29-2.14(m,2H),1.89-1.67(m,6H).
[0204] III. ADP Glo Kinase Assay for ASK1
[0205] Screening Method: ADP-GLO luminescent kinase assay, which detects ADP formed in the kinase reaction, which is converted into ATP, and then ATP is converted into light by Ultra-Glo luciferase.
[0206] Instruments: Multifunctional microplate reader (2104 Multilabel Reader, PerkinElmer, USA); biochemical incubator purchased from Biochemical incubator Company; ultrasonic nanoliter liquid processing system purchased from Echo Company.
[0207] Materials: ADP-GloTM kit (Promega USA); ASK1 kinase, purchased from Eurofins.
[0208] Principle: After the kinase reaction, the remaining ATP is completely consumed by the ADP-Glo reagent, and then ADP is converted into ATP, and the energy of ATP is transferred to the luciferin, so that Ultra-GloTM luciferase is converted into light. The luminescent signal is positively correlated with the kinase activity. ADP-GloTM can detect the activity of any enzyme that generates ADP, without the need for antibody participation and radioactive labeling.
[0209] Sample treatment: The sample is dissolved in DMSO and stored at low temperature. The concentration of DMSO in the final system is controlled within the range that does not affect the ADP-GloTM reagent.
[0210] ASK1 and substrate were diluted with HTRF kinase buffer (1X Kinase buffer, 25mM MgCl2, 4mM DTT, 20mM HEPES, pH7.5, 0.01% Triton x-100). 40μL of compound was transferred from the source plate to a new 384-well plate as an intermediate plate, and 50nl of compound was transferred to the assay plate by Echo. ASK1 solution was prepared in 1x kinase buffer at a concentration of 2 times the final concentration of each reagent, and 2.5μL of kinase solution was added to each well of the assay plate. Substrate solutions of MBP substrate and ATP were prepared in 1x kinase reaction buffer at a concentration of 4 times the final concentration, and the concentration of each reagent required in the assay. Add 2.5 μL of substrate solution to each well of the assay plate to start the reaction, shake the plate, incubate at 37°C for 60 min, add 5 μL of ADP-Glo reagent, incubate at 37°C for 180 min, then add 10 μL of kinase assay reagent, equilibrate at room temperature for 30 min to convert ADP to ATP and introduce luciferase and luciferin to check for ATP. Collect data on Envision. Convert RLU values to percent inhibition values and fit data in XLFit excel add-in version 5.4.0.8 to obtain IC 50 The value is calculated using the formula: Y = bottom + (top - bottom) / (1 + (IC 50 / X)^ hillside). The results are shown in Table 2 below.
[0211] Table 2
[0212]
[0213]
[0214] Note: In the table, * indicates IC 50 >2001nM; ** is 501-2000nM; *** indicates IC 50 50-500nM; **** means <50nM, ***** means <20nM.
Claims
1. A method having 1 H - a compound of a benzimidazole structure, or an enantiomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, characterized in that: The general structural formula of the compound is as follows: , in, R1 is selected from any one or a combination of the following: H, alkyl, aromatic acyl, aromatic alkyl, phenyl formate, formamide, substituted or unsubstituted 5-12 membered heteroaromatic ring containing N, O or S atoms, substituted or unsubstituted 5-13 membered saturated heterocyclic ring containing N, O or S atoms, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl, substituted or unsubstituted C2-C4 alkynyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkylethynyl, substituted or unsubstituted C1-C4 alkylamino, substituted or unsubstituted C1-C4 alkylcarbonylamino, substituted or unsubstituted C1-C4 alkoxycarbonylamino, substituted or unsubstituted C1-C4 sulfonyl, substituted or unsubstituted C1-C4 alkyl-S-, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C1-C4 alkylaminocarbonyl; R2 is selected from any one or a combination of the following: halogen, hydroxyl, amino, nitro, oxy, alkyl, substituted or unsubstituted 5-12 membered heteroaromatic ring containing N, O or S atoms, substituted or unsubstituted 5-13 membered saturated heterocyclic ring containing N, O or S atoms, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl, substituted or unsubstituted C2-C4 alkynyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkylethynyl, substituted or unsubstituted C1-C4 alkylamino, substituted or unsubstituted C1-C4 alkylcarbonylamino, substituted or unsubstituted C1-C4 alkoxycarbonylamino, substituted or unsubstituted C1-C4 sulfonyl, substituted or unsubstituted C1-C4 alkyl-S-, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C1-C4 alkylaminocarbonyl; A means S or O; It represents a 6-membered aromatic ring containing 0-2 N atoms, including but not limited to benzene ring, pyridine, pyrazine, and the N atoms are substituted at different positions on the ring; R3 represents a substituted or unsubstituted 5-6 membered heteroaromatic ring containing 1-4 heteroatoms of N, O or S, wherein one or more hydrogen atoms on the substituent group of the 5-6 membered heteroaromatic ring containing 1-4 heteroatoms of N, O or S are substituted by a group selected from the group consisting of halogen, deuterium atom, cyano, hydroxyl, amino, nitro, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy; wherein one or more hydrogen atoms on the substituent group of the substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy are substituted by a group selected from the group consisting of hydroxyl, amino, carboxyl.
2. The compound according to claim 1, characterized in that: The compounds include the general structural formulas (I-1) and (I-2): 。 3. A method having 1 H - a compound of a benzimidazole structure, or an enantiomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, characterized in that: The compound is selected from one of the following structural formulas: 。 4. A method for preparing a compound according to any one of claims 1 to 3, characterized in that: The steps include: 。 5. The method for preparing the compound according to claim 4, characterized in that: The compound of formula (I) is prepared by a one-step reaction in step 1, wherein step 1 is route 1 or route 2: The first route comprises: mixing carboxylic acid S1 and corresponding amine S2 in a solvent, adding 1-propyl phosphoric anhydride or 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, adding a base, and reacting at room temperature or 40°C to obtain a compound represented by formula (I-1); The second route comprises: mixing carboxylic acid S1 and corresponding amine S2 in a solvent, adding a base or phosphorus oxychloride, and reacting at room temperature or at 40°C to obtain a compound represented by formula (I-1); The step 2 comprises: adding the compound of formula (I-1) and Lawesson's reagent into toluene, raising the temperature to reflux and stirring overnight, and reacting to obtain the compound of formula (I-2).
6. The method for preparing the compound according to claim 4, characterized in that: The preparation of the carboxylic acid S1 comprises the following steps: , The step 1 comprises: adding 2-hydroxyacetic acid and 5.5M HCl solution to a reaction bottle containing compound M1, heating to reflux, and maintaining the reaction for 12 hours, cooling to room temperature, adding ammonia water dropwise until a precipitate is formed, filtering the precipitate, washing with water, and finally drying to obtain product M2, wherein the product M2 is directly used for the next reaction; the equivalent ratio of compound M1 to 2-hydroxyacetic acid is 1:1.5; Step 2: Mix the product M2 with aqueous base, stir at 100℃ for 2 h, cool to room temperature and add KMnO 4: The product is oxidized and then heated to 100°C for reaction for 10 hours. After the reaction is completed, the product is cooled to room temperature, the insoluble solid is filtered out, and the filtrate is adjusted to pH 4 with 2M HCl to produce a precipitate. The precipitated solid is collected by filtration, washed with water, and dried to obtain carboxylic acid S1. The equivalent ratio of the base, product M2, and KMnO4 is 2:1:1.5, and the aqueous base includes a 1N sodium hydroxide aqueous solution.
7. The method for preparing the compound according to claim 5, characterized in that: The solvent is any one of the following substances: tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, or N, N-dimethylformamide, toluene, pyridine; the base is any one of the following substances: triethylamine, diisopropylethylamine.
8. An ASK1 inhibitor, characterized in that: The inhibitor includes a compound as described in any one of claims 1 to 3, or an enantiomer, diastereomer, racemate and a mixture thereof, or a pharmaceutically acceptable salt, crystalline hydrate or solvate thereof.
9. A pharmaceutical composition, characterized in that include: (A) a therapeutically effective amount of the compound of claim 1, 2 or 3, or one or more of its enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof; and (B) a pharmaceutically acceptable carrier.
10. Use of the compound according to any one of claims 1 to 3 in the preparation of a drug for treating a disease associated with the activity or expression of ASK1 kinase, characterized in that: The disease associated with the activity or expression of ASK1 kinase is selected from one of liver disease, lung disease, cardiovascular disease, kidney disease, metabolic disease and tumor disease.
